Literature DB >> 24890835

Clinical characteristics and current treatment of glaucoma.

Laura P Cohen1, Louis R Pasquale2.   

Abstract

Glaucoma is a neurodegenerative disorder in which degenerating retinal ganglion cells (RGC) produce significant visual disability. Clinically, glaucoma refers to an array of conditions associated with variably elevated intraocular pressure (IOP) that contributes to RGC loss via mechanical stress, vascular abnormalities, and other mechanisms, such as immune phenomena. The clinical diagnosis of glaucoma requires assessment of the ocular anterior segment with slit lamp biomicroscopy, which allows the clinician to recognize signs of conditions that can produce elevated IOP. After measurement of IOP, a specialized prismatic lens called a gonioscope is used to determine whether the angle is physically open or closed. The structural manifestation of RGC loss is optic nerve head atrophy and excavation of the neuroretinal rim tissue. Treatment is guided by addressing secondary causes for elevated IOP (such as inflammation, infection, and ischemia) whenever possible. Subsequently, a variety of medical, laser, and surgical options are used to achieve a target IOP.
Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24890835      PMCID: PMC4031956          DOI: 10.1101/cshperspect.a017236

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  54 in total

1.  Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004.

Authors:  Pradeep Y Ramulu; Kevin J Corcoran; Suzanne L Corcoran; Alan L Robin
Journal:  Ophthalmology       Date:  2007-04-27       Impact factor: 12.079

2.  Acquired color vision changes in glaucoma. Use of 100-hue test and Pickford anomaloscope as predictors of glaucomatous field change.

Authors:  S M Drance; R Lakowski; M Schulzer; G R Douglas
Journal:  Arch Ophthalmol       Date:  1981-05

3.  Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons.

Authors:  L A Kerrigan-Baumrind; H A Quigley; M E Pease; D F Kerrigan; R S Mitchell
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

4.  Central corneal thickness of Caucasians and African Americans in glaucomatous and nonglaucomatous populations.

Authors:  F A La Rosa; R L Gross; S Orengo-Nania
Journal:  Arch Ophthalmol       Date:  2001-01

5.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

6.  The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology.

Authors:  David F Garway-Heath; Gerassimos Lascaratos; Catey Bunce; David P Crabb; Richard A Russell; Ameet Shah
Journal:  Ophthalmology       Date:  2012-09-15       Impact factor: 12.079

7.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

8.  Longitudinal analysis of progression in glaucoma using spectral-domain optical coherence tomography.

Authors:  Julia M Wessel; Folkert K Horn; Ralf P Tornow; Matthias Schmid; Christian Y Mardin; Friedrich E Kruse; Anselm G Juenemann; Robert Laemmer
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-01       Impact factor: 4.799

9.  Clinical impact of 8 prospective, randomized, multicenter glaucoma trials.

Authors:  Joseph F Panarelli; Michael R Banitt; Paul A Sidoti; Donald L Budenz; Kuldev Singh
Journal:  J Glaucoma       Date:  2015-01       Impact factor: 2.503

10.  Intraocular pressure elevation associated with inhalation and nasal corticosteroids.

Authors:  I Opatowsky; R M Feldman; R Gross; S T Feldman
Journal:  Ophthalmology       Date:  1995-02       Impact factor: 12.079

View more
  38 in total

1.  Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery.

Authors:  Xuesong Qiao; Xiaoting Peng; Jing Qiao; Zhiwen Jiang; Baoqin Han; Chaozhong Yang; Wanshun Liu
Journal:  J Mater Sci Mater Med       Date:  2017-08-22       Impact factor: 3.896

2.  Optogenetic Stimulation of the Superior Colliculus Confers Retinal Neuroprotection in a Mouse Glaucoma Model.

Authors:  Emiel Geeraerts; Marie Claes; Eline Dekeyster; Manuel Salinas-Navarro; Lies De Groef; Chris Van den Haute; Isabelle Scheyltjens; Veerle Baekelandt; Lutgarde Arckens; Lieve Moons
Journal:  J Neurosci       Date:  2019-01-17       Impact factor: 6.167

Review 3.  Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.

Authors:  Megan Kim; Chelsea Lee; Rachael Payne; Beatrice Y J T Yue; Jin-Hong Chang; Hongyu Ying
Journal:  Surv Ophthalmol       Date:  2015-05-15       Impact factor: 6.048

4.  Effect of ocular hypertension on the pattern of retinal ganglion cell subtype loss in a mouse model of early-onset glaucoma.

Authors:  S Daniel; K J Meyer; A F Clark; M G Anderson; C M McDowell
Journal:  Exp Eye Res       Date:  2019-06-15       Impact factor: 3.467

5.  MIND diet lowers risk of open-angle glaucoma: the Rotterdam Study.

Authors:  Joëlle E Vergroesen; Tosca O E de Crom; Cornelia M van Duijn; Trudy Voortman; Caroline C W Klaver; Wishal D Ramdas
Journal:  Eur J Nutr       Date:  2022-09-20       Impact factor: 4.865

6.  Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.

Authors:  Jessica A Cooke; Jason S Meyer
Journal:  Curr Ophthalmol Rep       Date:  2015-08-07

7.  Down-regulated LAMA4 inhibits oxidative stress-induced apoptosis of retinal ganglion cells through the MAPK signaling pathway in rats with glaucoma.

Authors:  Chong Wang; Ya-Lin Ren; Jin Zhai; Xiao-Yan Zhou; Jing Wu
Journal:  Cell Cycle       Date:  2019-04-19       Impact factor: 5.173

8.  Systemic Treatment with Nicotinamide Riboside Is Protective in Two Mouse Models of Retinal Ganglion Cell Damage.

Authors:  Xian Zhang; Nan Zhang; Micah A Chrenek; Preston E Girardot; Jiaxing Wang; Jana T Sellers; Eldon E Geisert; Charles Brenner; John M Nickerson; Jeffrey H Boatright; Ying Li
Journal:  Pharmaceutics       Date:  2021-06-16       Impact factor: 6.321

Review 9.  Carotenoids in the Management of Glaucoma: A Systematic Review of the Evidence.

Authors:  Drake W Lem; Dennis L Gierhart; Pinakin Gunvant Davey
Journal:  Nutrients       Date:  2021-06-06       Impact factor: 5.717

Review 10.  Retinal Organoids: Cultivation, Differentiation, and Transplantation.

Authors:  Xuying Li; Li Zhang; Fei Tang; Xin Wei
Journal:  Front Cell Neurosci       Date:  2021-06-28       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.